hydroxychloroquine - versus standard of care - for COVID-19 prophylaxis   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.68 [0.22, 2.08]< 10%1 study (1/-)75.2 %some concernnot evaluable moderatecrucial-
new illness compatible with Covid-19 0.86 [0.52, 1.42]< 10%1 study (1/-)72.2 %some concernnot evaluable moderateimportant-
PCR-confirmed, symptomatic Covid-19 disease 0.86 [0.52, 1.42]< 10%1 study (1/-)72.2 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

serious adverse events 0.89 [0.44, 1.82]< 10%1 study (1/-)62.2 %some concernnot evaluable moderateimportant-
adverse events 20.26 [15.67, 26.20]< 10%1 study (1/-)0.0 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 89 89